Intellectual property (IP) provisions that were pursued by the United States (US) in the Trans-Pacific Partnership Agreement (TPP) negotiations generated widespread alarm. Subsequent leaks of composite drafts of the IP chapter showed ongoing resistance by most countries to many of the US proposals that would delay access to generic medicines. A journal article in Australian […]
The 1994 Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) removed the option for member countries of the World Trade Organization (WTO) to exclude pharmaceutical patents. It also required members to introduce other limitations on pharmaceutical competition, such as protection for ‘test’ data submitted to support regulatory approval. Concerns have been raised that […]
Japan’s recent role in promoting the expansion of intellectual property rights (IPR) in regional trade agreements signals a shift in the landscape once dominated by the United States (US) and European Union (EU). Japan was a latecomer to the Trans Pacific Partnership Agreement (TPP) but has played a key role in attempting to revive the […]
By Son K-B, Lopert R, Gleeson D, Lee T-J. Globalization and Health, 14:101.
Transnational corporations (TNCs) have moved to the forefront of regulatory governance both within states and in the international arena. The Research Handbook on Transnational Corporations provides expert background commentary and up-to-date insights into regulatory frameworks impacting on TNCs at global, industry and national levels. Written by global experts in their field, this unique collection of […]
The inclusion of elevated standards of intellectual property (IP) protection in the recently negotiated Trans-Pacific Partnership (TPP) agreement has raised serious public health concerns regarding access to medicines. A lesser-known trade agreement that went into effect in January 2022 in the Asia-Pacific region is the Regional Comprehensive Economic Partnership (RCEP). Framed as an attempt to […]
Throughout the negotiations for the Trans-Pacific Partnership Agreement (TPP), the United States’ (US) advocacy for intellectual property (IP) provisions generated widespread alarm. The leaked draft of the IP chapter showed ongoing resistance by most countries to many of the US proposals that would delay access to generic medicines. While later leaked drafts suggested some modifications […]
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) has been highly controversial since it was concluded in 1995. Since then, the United States’ pursuit of higher intellectual property (IP) protection (TRIPS-Plus) for medicines in bilateral and multilateral agreements has been well recognized. As a result, the proliferation of post-TRIPS “free” trade agreements has […]
By Gleeson D, Lopert R, and Reid P. Health Policy 112(3): 227-233.